<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00330447</url>
  </required_header>
  <id_info>
    <org_study_id>cancer in pregnancy</org_study_id>
    <nct_id>NCT00330447</nct_id>
  </id_info>
  <brief_title>Effects of Oncological Treatment During Pregnancy on Mother and Child</brief_title>
  <official_title>Oncological Treatment During Pregnancy: Pharmacokinetics of Chemotherapy and Long Term Follow up of the Offspring</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Gasthuisberg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Laurence Claes, PhD</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ingrid Boere, MD PhD</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Michael Halaska, MD PhD</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lagae, Lieven, M.D., Ph.D.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mertens, Luc, M.D., Ph.D.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Monica Fumagalli, MD PhD</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kristel Van Calsteren, MD PhD</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Christianne Lok, MD PhD</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Robert Fruscio, MD PhD</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Marry van den Heuvel-Eibrink, MD PhD</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Gasthuisberg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The researchers aim to investigate the outcome (overall survival) of mothers who are
      diagnosed and/or treated for cancer during pregnancy. Furthermore they want to test the
      hypothesis that children who were exposed to cancer or cancer treatment (cytotoxic drugs,
      radiation therapy, targeted therapy,...) develop normally (neurologic and cardiologic
      examination).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study contains several study parts (protocol version 4.2):

      **********Part I. Pregnancy, delivery and maternal health********** Part I.I.A. Registration
      study 'Cancer during pregnancy' mother and neonate None Part I.I.B. Effects of prenatal
      exposure to cancer treatment on fetal growth. The association between placental
      pathophysiologic mechanisms (histopathology and immunohistochemistry), circulating maternal
      factors and fetal growth.

      From participating women, a maternal blood sample will be collected during or shortly after
      birth. Also, an umbilical cord blood sample and placental and umbilical cord biopsies will be
      drawn.

      Part I.II. Measurement of maternal and paternal anxiety and emotional needs when confronted
      with a cancer diagnosis during pregnancy The participants will be asked to complete
      questionnaires. Part I.III. Biobank 'cancer and pregnancy' From participating women, a tumour
      biopsy specimen before administration of neoadjuvant therapy will be collected at the time of
      diagnosis. Also, maternal blood samples will be collected before and/or after treatment.

      Part I.IV. Study on the pharmacokinetics of chemotherapeutic agents in pregnant women
      Approximately 10-12 additional peripheral venous blood withdrawals.

      **********Part II. Child********** Long term follow up of children and adolescents in utero
      exposed to chemotherapy and/or radiotherapy Regular check-ups of the child, at the age of
      18months, 3y, 6y, 9y, 12y, 15y, and 18y, and after the age of 18 years: 5-yearly cardiologic
      assessment and questionnaires (23y, 28y, 33y, 38y, and 43y). Optional at the ages of 9y, 12y,
      15y and 18y: MRI session.

      Summary part I:

      Prospectively the outcome of mothers diagnosed and/or treated for cancer during pregnancy
      will be registered and investigated.

      Summary Part II:

      In a prospective trial we invite children that were exposed to cytotoxic drugs or
      radiotherapy in utero for a standardized neurological and cardiological examination. The
      examinations will be done by qualified psychologists, neurological and cardiological
      pediatricians.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2005</start_date>
  <completion_date type="Anticipated">December 2032</completion_date>
  <primary_completion_date type="Anticipated">April 2025</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>18 Years</target_duration>
  <primary_outcome>
    <measure>Follow-up of the mothers diagnosed with cancer during pregnancy</measure>
    <time_frame>anticipated</time_frame>
    <description>treatment during pregnancy, obstetrical outcome, maternal survival</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Follow-up of the children antenatally exposed to chemotherapy or radiotherapy</measure>
    <time_frame>anticipated</time_frame>
    <description>neurologic and cardiologic outcome</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>Cancer</condition>
  <condition>Pregnancy</condition>
  <arm_group>
    <arm_group_label>Studygroup</arm_group_label>
    <description>Cancer in Pregnancy - all diagnoses and treatments Children born from mothers diagnosed with cancer during pregnancy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>Children from the general population</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Maternal blood serum and sediment of blood; from 2010 on we collect umbilical cord blood.

      Since new approval of protocol version 4.2 (08-02-2018) we collect samples of placental
      tissue, umbilical cord tissue and membranes.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Premenopausal women with a cancer diagnosis in association with cancer
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Patients do not need to participate in both; however, preferentially both study parts
        should be performed.

        **************Part I: Pregnancy, delivery and maternal health**************

        Patients must meet the following inclusion criteria:

          -  Histologically proven cancer in association with a pregnancy (during pregnancy or
             cancer dagnosis within 5 years after pregnancy)

          -  &gt; 18 years of age, premenopausal

          -  Patients who have given their signed and written informed consent to participate in
             the trial after fully understanding the implication of the protocol

          -  Women receiving any cytotoxic drug or radiation therapy during pregnancy are allowed
             for the assessment of the maternal and fetal outcome (Part II).

        Exclusion Criteria:

          -  Mentally disabled or significantly altered mental status that would prohibit the
             understanding and giving of informed consent

        **************Part II: Follow-up of children**************

        Inclusion Criteria:

        - Children that were prenatally exposed to cancer of cancer treament. Informed Consent is
        asked from parents.

        Exclusion Criteria:

          -  Mentally disabled or significantly altered mental status that would prohibit the
             understanding and giving of informed consent
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amant Frederic, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>KULeuven, Belgium</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Katrien Van Tornout</last_name>
    <phone>+32-16-342876</phone>
    <email>katrien.vantornout@uzleuven.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kristel Van Calsteren, MD PhD</last_name>
    <phone>+32-16-346192</phone>
    <email>kristel.vancalsteren@uzleuven.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UCL Brussels</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mina Mhallem</last_name>
      <email>katrien.vantornout@uzleuven.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZ Gasthuisberg, Katholieke Universiteit Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frederic Amant, MD, PhD</last_name>
      <phone>+32-16-344252</phone>
      <email>frederic.amant@uzleuven.be</email>
    </contact>
    <contact_backup>
      <last_name>Kristel Van Calsteren, MD, PhD</last_name>
      <phone>+32-16-346192</phone>
      <email>kristel.vancalsteren@uzleuven.be</email>
    </contact_backup>
    <investigator>
      <last_name>Lieven Lagae, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luc Mertens, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frederic Amant, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kristel Van Calsteren, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Halaska, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laurence Claes, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Monica Fumagalli, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Regional Hospital of High Specialty of Ixtapaluca</name>
      <address>
        <city>Ixtapaluca</city>
        <zip>56530</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Álvaro Cabrera Garciá, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ingrid Boere, MD PHD</last_name>
      <email>cip@nki.nl</email>
    </contact>
    <investigator>
      <last_name>Frédéric Amant, MD PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>C.A.R. Lok, MD PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>M.M. Van den Heuvel-Eibrink, MD PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>C.J.M. De Groot, MD PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>R.C. Painter, MD PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>P.B. Ottevanger, MD PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>P.O. Witteveen, MD PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>C.P. Schröder, MD PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>S.J. Gordijn, MD PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>J. Kroep, MD PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>R.L.M. Bekkers, MD PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>A.M.J. Thijs, MD PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Center for Obstetrics, Gynecology and Perinatology</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roman Shmakov, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Russian Federation</country>
  </location_countries>
  <link>
    <url>http://www.cancerinpregnancy.org</url>
    <description>This site provides background information on the problem of cancer in pregnancy and details further the project.</description>
  </link>
  <reference>
    <citation>Caluwaerts S, VAN Calsteren K, Mertens L, Lagae L, Moerman P, Hanssens M, Wuyts K, Vergote I, Amant F. Neoadjuvant chemotherapy followed by radical hysterectomy for invasive cervical cancer diagnosed during pregnancy: report of a case and review of the literature. Int J Gynecol Cancer. 2006 Mar-Apr;16(2):905-8.</citation>
    <PMID>16681782</PMID>
  </reference>
  <reference>
    <citation>Van Calsteren K, Berteloot P, Hanssens M, Vergote I, Amant F, Ganame J, Claus P, Mertens L, Lagae L, Delforge M, Paridaens R, Noens L, Humblet Y, Vandermeersch B, De Muylder X. In utero exposure to chemotherapy: effect on cardiac and neurologic outcome. J Clin Oncol. 2006 Apr 20;24(12):e16-7.</citation>
    <PMID>16622256</PMID>
  </reference>
  <reference>
    <citation>Lishner M, Avivi I, Apperley JF, Dierickx D, Evens AM, Fumagalli M, Nulman I, Oduncu FS, Peccatori FA, Robinson S, Van Calsteren K, Vandenbroucke T, Van den Heuvel F, Amant F. Hematologic Malignancies in Pregnancy: Management Guidelines From an International Consensus Meeting. J Clin Oncol. 2016 Feb 10;34(5):501-8. doi: 10.1200/JCO.2015.62.4445. Epub 2015 Nov 30.</citation>
    <PMID>26628463</PMID>
  </reference>
  <reference>
    <citation>Amant F, Verheecke M, Wlodarska I, Dehaspe L, Brady P, Brison N, Van Den Bogaert K, Dierickx D, Vandecaveye V, Tousseyn T, Moerman P, Vanderstichele A, Vergote I, Neven P, Berteloot P, Putseys K, Danneels L, Vandenberghe P, Legius E, Vermeesch JR. Presymptomatic Identification of Cancers in Pregnant Women During Noninvasive Prenatal Testing. JAMA Oncol. 2015 Sep;1(6):814-9. doi: 10.1001/jamaoncol.2015.1883.</citation>
    <PMID>26355862</PMID>
  </reference>
  <reference>
    <citation>de Haan J, Verheecke M, Amant F. Management of ovarian cysts and cancer in pregnancy. Facts Views Vis Obgyn. 2015;7(1):25-31. Review.</citation>
    <PMID>25897369</PMID>
  </reference>
  <reference>
    <citation>Amant F, Han SN, Gziri MM, Vandenbroucke T, Verheecke M, Van Calsteren K. Management of cancer in pregnancy. Best Pract Res Clin Obstet Gynaecol. 2015 Jul;29(5):741-53. doi: 10.1016/j.bpobgyn.2015.02.006. Epub 2015 Mar 4. Review.</citation>
    <PMID>25797199</PMID>
  </reference>
  <reference>
    <citation>van Dam L, Han SN, Dierickx D, Amant F. Optimal staging of lymphoma during pregnancy is crucial. Womens Health (Lond). 2015 Mar;11(2):101-2. doi: 10.2217/whe.14.77.</citation>
    <PMID>25776282</PMID>
  </reference>
  <reference>
    <citation>Han SN, Van Peer S, Peccatori F, Gziri MM, Amant F; International Network on Cancer, Infertility and Pregnancy. Contraception is as important as fertility preservation in young women with cancer. Lancet. 2015 Feb 7;385(9967):508. doi: 10.1016/S0140-6736(15)60201-X.</citation>
    <PMID>25705843</PMID>
  </reference>
  <reference>
    <citation>Han SN, Verheecke M, Vandenbroucke T, Gziri MM, Van Calsteren K, Amant F. Management of gynecological cancers during pregnancy. Curr Oncol Rep. 2014 Dec;16(12):415. doi: 10.1007/s11912-014-0415-z. Review.</citation>
    <PMID>25344340</PMID>
  </reference>
  <reference>
    <citation>Van Calsteren K, Amant F. Cancer during pregnancy. Acta Obstet Gynecol Scand. 2014 May;93(5):443-6. doi: 10.1111/aogs.12380.</citation>
    <PMID>24628416</PMID>
  </reference>
  <reference>
    <citation>Amant F, Halaska MJ, Fumagalli M, Dahl Steffensen K, Lok C, Van Calsteren K, Han SN, Mir O, Fruscio R, Uzan C, Maxwell C, Dekrem J, Strauven G, Mhallem Gziri M, Kesic V, Berveiller P, van den Heuvel F, Ottevanger PB, Vergote I, Lishner M, Morice P, Nulman I; ESGO task force ‘Cancer in Pregnancy’. Gynecologic cancers in pregnancy: guidelines of a second international consensus meeting. Int J Gynecol Cancer. 2014 Mar;24(3):394-403. doi: 10.1097/IGC.0000000000000062. Review. Erratum in: Int J Gynecol Cancer. 2014 May;24(4):819.</citation>
    <PMID>24445819</PMID>
  </reference>
  <reference>
    <citation>Vandenbriele C, Dierickx D, Amant F, Delforge M. The treatment of hematologic malignancies in pregnancy. Facts Views Vis Obgyn. 2010;2(2):74-87. Review.</citation>
    <PMID>25302102</PMID>
  </reference>
  <reference>
    <citation>Deckers S, Amant F. Breast cancer in pregnancy: a literature review. Facts Views Vis Obgyn. 2009;1(2):130-41. Review.</citation>
    <PMID>25478078</PMID>
  </reference>
  <reference>
    <citation>Gziri MM, Goffin F, Debieve F, Amant F. [Cancer diagnosis during pregnancy: importance of a national and European registration]. Rev Med Liege. 2013 Oct;68(10):527-30. French.</citation>
    <PMID>24298727</PMID>
  </reference>
  <reference>
    <citation>Han SN, Kesic VI, Van Calsteren K, Petkovic S, Amant F; ESGO ‘Cancer in Pregnancy’ Task Force. Cancer in pregnancy: a survey of current clinical practice. Eur J Obstet Gynecol Reprod Biol. 2013 Mar;167(1):18-23. doi: 10.1016/j.ejogrb.2012.10.026. Epub 2012 Nov 19.</citation>
    <PMID>23182070</PMID>
  </reference>
  <reference>
    <citation>Han SN, Gziri MM, Van Calsteren K, Amant F. Is chemotherapy during the first trimester of pregnancy really safe? Int J Cancer. 2013 Apr 1;132(7):1728. doi: 10.1002/ijc.27815. Epub 2012 Sep 28.</citation>
    <PMID>22945483</PMID>
  </reference>
  <reference>
    <citation>Han SN, Lotgerink A, Gziri MM, Van Calsteren K, Hanssens M, Amant F. Physiologic variations of serum tumor markers in gynecological malignancies during pregnancy: a systematic review. BMC Med. 2012 Aug 8;10:86. doi: 10.1186/1741-7015-10-86.</citation>
    <PMID>22873292</PMID>
  </reference>
  <reference>
    <citation>Loibl S, Han SN, Amant F. Being Pregnant and Diagnosed with Breast Cancer. Breast Care (Basel). 2012 Jun;7(3):204-209. Epub 2012 Jun 27.</citation>
    <PMID>22872793</PMID>
  </reference>
  <reference>
    <citation>Amant F. Safety of chemotherapy in pregnancy. Clin Adv Hematol Oncol. 2012 Apr;10(4):258-9.</citation>
    <PMID>22706488</PMID>
  </reference>
  <reference>
    <citation>Verheecke M, Hermans E, Tuyaerts S, Souche E, Van Bree R, Verbist G, Everaert T, Van Houdt J, Van Calsteren K, Amant F. Acute Drug Effects on the Human Placental Tissue: The Development of a Placental Murine Xenograft Model. Reprod Sci. 2018 Jan 1:1933719118756771. doi: 10.1177/1933719118756771. [Epub ahead of print]</citation>
    <PMID>29439620</PMID>
  </reference>
  <reference>
    <citation>Boere I, Lok C, Vandenbroucke T, Amant F. Cancer in pregnancy: safety and efficacy of systemic therapies. Curr Opin Oncol. 2017 Sep;29(5):328-334. doi: 10.1097/CCO.0000000000000386. Review.</citation>
    <PMID>28614135</PMID>
  </reference>
  <reference>
    <citation>Fruscio R, de Haan J, Van Calsteren K, Verheecke M, Mhallem M, Amant F. Ovarian cancer in pregnancy. Best Pract Res Clin Obstet Gynaecol. 2017 May;41:108-117. doi: 10.1016/j.bpobgyn.2016.09.013. Epub 2016 Oct 1. Review.</citation>
    <PMID>28029502</PMID>
  </reference>
  <reference>
    <citation>Vercruysse DC, Deprez S, Sunaert S, Van Calsteren K, Amant F. Effects of prenatal exposure to cancer treatment on neurocognitive development, a review. Neurotoxicology. 2016 May;54:11-21. doi: 10.1016/j.neuro.2016.02.013. Epub 2016 Mar 4. Review.</citation>
    <PMID>26952827</PMID>
  </reference>
  <reference>
    <citation>de Haan J, Vandecaveye V, Han SN, Van de Vijver KK, Amant F. Difficulties with diagnosis of malignancies in pregnancy. Best Pract Res Clin Obstet Gynaecol. 2016 May;33:19-32. doi: 10.1016/j.bpobgyn.2015.10.005. Epub 2015 Oct 19. Review.</citation>
    <PMID>26586541</PMID>
  </reference>
  <reference>
    <citation>Han SN, Mhallem Gziri M, Van Calsteren K, Amant F. Cervical cancer in pregnant women: treat, wait or interrupt? Assessment of current clinical guidelines, innovations and controversies. Ther Adv Med Oncol. 2013 Jul;5(4):211-9. doi: 10.1177/1758834013494988.</citation>
    <PMID>23858330</PMID>
  </reference>
  <reference>
    <citation>Amant F, Han SN, Gziri MM, Dekrem J, Van Calsteren K. Chemotherapy during pregnancy. Curr Opin Oncol. 2012 Sep;24(5):580-6. doi: 10.1097/CCO.0b013e328354e754. Review.</citation>
    <PMID>22581358</PMID>
  </reference>
  <reference>
    <citation>Amant F, Loibl S, Neven P, Van Calsteren K. Breast cancer in pregnancy. Lancet. 2012 Feb 11;379(9815):570-9. doi: 10.1016/S0140-6736(11)61092-1. Review.</citation>
    <PMID>22325662</PMID>
  </reference>
  <reference>
    <citation>Han SN, Van Calsteren K, Amant F. Use of chemotherapy during pregnancy in the treatment of ovarian malignancies. Eur J Obstet Gynecol Reprod Biol. 2011 Jun;156(2):237. doi: 10.1016/j.ejogrb.2011.02.004. Epub 2011 Mar 25.</citation>
    <PMID>21439708</PMID>
  </reference>
  <reference>
    <citation>Amant F, Deckers S, Van Calsteren K, Loibl S, Halaska M, Brepoels L, Beijnen J, Cardoso F, Gentilini O, Lagae L, Mir O, Neven P, Ottevanger N, Pans S, Peccatori F, Rouzier R, Senn HJ, Struikmans H, Christiaens MR, Cameron D, Du Bois A. Breast cancer in pregnancy: recommendations of an international consensus meeting. Eur J Cancer. 2010 Dec;46(18):3158-68. doi: 10.1016/j.ejca.2010.09.010.</citation>
    <PMID>20932740</PMID>
  </reference>
  <reference>
    <citation>Amant F, Brepoels L, Halaska MJ, Gziri MM, Calsteren KV. Gynaecologic cancer complicating pregnancy: an overview. Best Pract Res Clin Obstet Gynaecol. 2010 Feb;24(1):61-79. doi: 10.1016/j.bpobgyn.2009.08.001. Epub 2009 Sep 8. Review.</citation>
    <PMID>19740709</PMID>
  </reference>
  <reference>
    <citation>Van Calsteren K, Hartmann D, Van Aerschot L, Verbesselt R, Van Bree R, D'Hooge R, Amant F. Vinblastine and doxorubicin administration to pregnant mice affects brain development and behaviour in the offspring. Neurotoxicology. 2009 Jul;30(4):647-57. doi: 10.1016/j.neuro.2009.04.009. Epub 2009 May 5.</citation>
    <PMID>19422850</PMID>
  </reference>
  <reference>
    <citation>Amant F, Van Calsteren K, Halaska MJ, Beijnen J, Lagae L, Hanssens M, Heyns L, Lannoo L, Ottevanger NP, Vanden Bogaert W, Ungar L, Vergote I, du Bois A. Gynecologic cancers in pregnancy: guidelines of an international consensus meeting. Int J Gynecol Cancer. 2009 May;19 Suppl 1:S1-12. doi: 10.1111/IGC.0b013e3181a1d0ec.</citation>
    <PMID>19509538</PMID>
  </reference>
  <reference>
    <citation>Van Calsteren K, Devlieger R, De Catte L, D'Hooghe T, Chai DC, Mwenda JM, Vergote I, Amant F. Feasibility of ultrasound-guided percutaneous samplings in the pregnant baboon: a model for studies on transplacental transport. Reprod Sci. 2009 Mar;16(3):280-5. doi: 10.1177/1933719108324890. Epub 2008 Dec 15.</citation>
    <PMID>19087981</PMID>
  </reference>
  <reference>
    <citation>Amant F, Van Calsteren K, Vergote I, Ottevanger N. Gynecologic oncology in pregnancy. Crit Rev Oncol Hematol. 2008 Sep;67(3):187-95. doi: 10.1016/j.critrevonc.2008.01.006. Epub 2008 Mar 4. Review.</citation>
    <PMID>18296060</PMID>
  </reference>
  <results_reference>
    <citation>Van Calsteren K, Heyns L, De Smet F, Van Eycken L, Gziri MM, Van Gemert W, Halaska M, Vergote I, Ottevanger N, Amant F. Cancer during pregnancy: an analysis of 215 patients emphasizing the obstetrical and the neonatal outcomes. J Clin Oncol. 2010 Feb 1;28(4):683-9. doi: 10.1200/JCO.2009.23.2801. Epub 2009 Oct 19.</citation>
    <PMID>19841323</PMID>
  </results_reference>
  <results_reference>
    <citation>Amant F, Van Calsteren K, Halaska MJ, Gziri MM, Hui W, Lagae L, Willemsen MA, Kapusta L, Van Calster B, Wouters H, Heyns L, Han SN, Tomek V, Mertens L, Ottevanger PB. Long-term cognitive and cardiac outcomes after prenatal exposure to chemotherapy in children aged 18 months or older: an observational study. Lancet Oncol. 2012 Mar;13(3):256-64. doi: 10.1016/S1470-2045(11)70363-1. Epub 2012 Feb 10.</citation>
    <PMID>22326925</PMID>
  </results_reference>
  <results_reference>
    <citation>Gziri MM, Debiève F, DE Catte L, Mertens L, Barrea C, VAN Calsteren K, Han SN, Heyns L, Amant F. Chemotherapy during pregnancy: effect of anthracyclines on fetal and maternal cardiac function. Acta Obstet Gynecol Scand. 2012 Dec;91(12):1465-8. doi: 10.1111/j.1600-0412.2012.01524.x. Epub 2012 Nov 1.</citation>
    <PMID>22880883</PMID>
  </results_reference>
  <results_reference>
    <citation>Loibl S, Han SN, von Minckwitz G, Bontenbal M, Ring A, Giermek J, Fehm T, Van Calsteren K, Linn SC, Schlehe B, Gziri MM, Westenend PJ, Müller V, Heyns L, Rack B, Van Calster B, Harbeck N, Lenhard M, Halaska MJ, Kaufmann M, Nekljudova V, Amant F. Treatment of breast cancer during pregnancy: an observational study. Lancet Oncol. 2012 Sep;13(9):887-96. doi: 10.1016/S1470-2045(12)70261-9. Epub 2012 Aug 16.</citation>
    <PMID>22902483</PMID>
  </results_reference>
  <results_reference>
    <citation>Gziri MM, Amant F, Debiève F, Van Calsteren K, De Catte L, Mertens L. Effects of chemotherapy during pregnancy on the maternal and fetal heart. Prenat Diagn. 2012 Jul;32(7):614-9. doi: 10.1002/pd.3847. Epub 2012 Apr 17. Review.</citation>
    <PMID>22508540</PMID>
  </results_reference>
  <results_reference>
    <citation>Mhallem Gziri M, Han SN, Van Calsteren K, Heyns L, Delaere P, Nuyts S, Van den Heuvel F, Cheron AC, Fossion E, Van den Weyngaert D, Lok C, Amant F. Tongue cancers during pregnancy: Case reports and review of literature. Head Neck. 2013 Apr;35(4):E102-8. doi: 10.1002/hed.21924. Epub 2011 Oct 19. Review.</citation>
    <PMID>22009853</PMID>
  </results_reference>
  <results_reference>
    <citation>Gziri MM, Hui W, Amant F, Van Calsteren K, Ottevanger N, Kapusta L, Mertens L. Myocardial function in children after fetal chemotherapy exposure. A tissue Doppler and myocardial deformation imaging study. Eur J Pediatr. 2013 Feb;172(2):163-70. doi: 10.1007/s00431-012-1849-7. Epub 2012 Oct 5.</citation>
    <PMID>23052619</PMID>
  </results_reference>
  <results_reference>
    <citation>Boussios S, Han SN, Fruscio R, Halaska MJ, Ottevanger PB, Peccatori FA, Koubková L, Pavlidis N, Amant F. Lung cancer in pregnancy: report of nine cases from an international collaborative study. Lung Cancer. 2013 Dec;82(3):499-505. doi: 10.1016/j.lungcan.2013.09.002. Epub 2013 Sep 12.</citation>
    <PMID>24091171</PMID>
  </results_reference>
  <results_reference>
    <citation>Amant F, von Minckwitz G, Han SN, Bontenbal M, Ring AE, Giermek J, Wildiers H, Fehm T, Linn SC, Schlehe B, Neven P, Westenend PJ, Müller V, Van Calsteren K, Rack B, Nekljudova V, Harbeck N, Untch M, Witteveen PO, Schwedler K, Thomssen C, Van Calster B, Loibl S. Prognosis of women with primary breast cancer diagnosed during pregnancy: results from an international collaborative study. J Clin Oncol. 2013 Jul 10;31(20):2532-9. doi: 10.1200/JCO.2012.45.6335. Epub 2013 Apr 22.</citation>
    <PMID>23610117</PMID>
  </results_reference>
  <results_reference>
    <citation>Verheecke M, Halaska MJ, Lok CA, Ottevanger PB, Fruscio R, Dahl-Steffensen K, Kolawa W, Gziri MM, Han SN, Van Calsteren K, Van den Heuvel F, De Vleeschouwer S, Clement PM, Menten J, Amant F; ESGO Task Force ‘Cancer in Pregnancy’. Primary brain tumours, meningiomas and brain metastases in pregnancy: report on 27 cases and review of literature. Eur J Cancer. 2014 May;50(8):1462-71. doi: 10.1016/j.ejca.2014.02.018. Epub 2014 Mar 14. Review.</citation>
    <PMID>24636876</PMID>
  </results_reference>
  <results_reference>
    <citation>Vandenbroucke T, Van Calsteren K, Amant F. Pediatric Outcome after Maternal Cancer Diagnosed during Pregnancy. N Engl J Med. 2016 Feb 18;374(7):693. doi: 10.1056/NEJMc1515462.</citation>
    <PMID>26886537</PMID>
  </results_reference>
  <results_reference>
    <citation>Amant F, Vandenbroucke T, Verheecke M, Fumagalli M, Halaska MJ, Boere I, Han S, Gziri MM, Peccatori F, Rob L, Lok C, Witteveen P, Voigt JU, Naulaers G, Vallaeys L, Van den Heuvel F, Lagae L, Mertens L, Claes L, Van Calsteren K; International Network on Cancer, Infertility, and Pregnancy (INCIP). Pediatric Outcome after Maternal Cancer Diagnosed during Pregnancy. N Engl J Med. 2015 Nov 5;373(19):1824-34. doi: 10.1056/NEJMoa1508913. Epub 2015 Sep 28.</citation>
    <PMID>26415085</PMID>
  </results_reference>
  <results_reference>
    <citation>Loibl S, Schmidt A, Gentilini O, Kaufman B, Kuhl C, Denkert C, von Minckwitz G, Parokonnaya A, Stensheim H, Thomssen C, van Calsteren K, Poortmans P, Berveiller P, Markert UR, Amant F. Breast Cancer Diagnosed During Pregnancy: Adapting Recent Advances in Breast Cancer Care for Pregnant Patients. JAMA Oncol. 2015 Nov;1(8):1145-53. doi: 10.1001/jamaoncol.2015.2413. Erratum in: JAMA Oncol. 2015 Nov;1(8):1172.</citation>
    <PMID>26247818</PMID>
  </results_reference>
  <results_reference>
    <citation>Vandenbroucke T, Amant F. Development of children born to mothers with cancer during pregnancy: comparing in utero chemotherapy-exposed children with nonexposed controls. Am J Obstet Gynecol. 2015 Jun;212(6):830-1. doi: 10.1016/j.ajog.2015.01.035. Epub 2015 Jan 28.</citation>
    <PMID>25637847</PMID>
  </results_reference>
  <results_reference>
    <citation>Vandenbroucke T, Verheecke M, Van Calsteren K, Han S, Claes L, Amant F. Fetal outcome after prenatal exposure to chemotherapy and mechanisms of teratogenicity compared to alcohol and smoking. Expert Opin Drug Saf. 2014 Dec;13(12):1653-65. doi: 10.1517/14740338.2014.965677. Epub 2014 Nov 10. Review.</citation>
    <PMID>25382454</PMID>
  </results_reference>
  <results_reference>
    <citation>van Hasselt JG, van Calsteren K, Heyns L, Han S, Mhallem Gziri M, Schellens JH, Beijnen JH, Huitema AD, Amant F. Optimizing anticancer drug treatment in pregnant cancer patients: pharmacokinetic analysis of gestation-induced changes for doxorubicin, epirubicin, docetaxel and paclitaxel. Ann Oncol. 2014 Oct;25(10):2059-65. doi: 10.1093/annonc/mdu140. Epub 2014 Apr 8.</citation>
    <PMID>24713311</PMID>
  </results_reference>
  <results_reference>
    <citation>Dekrem J, Van Calsteren K, Amant F. Effects of fetal exposure to maternal chemotherapy. Paediatr Drugs. 2013 Oct;15(5):329-34. doi: 10.1007/s40272-013-0040-6. Review.</citation>
    <PMID>23856754</PMID>
  </results_reference>
  <results_reference>
    <citation>Gziri MM, Pokreisz P, De Vos R, Verbeken E, Debiève F, Mertens L, Janssens SP, Amant F. Fetal rat hearts do not display acute cardiotoxicity in response to maternal Doxorubicin treatment. J Pharmacol Exp Ther. 2013 Sep;346(3):362-9. doi: 10.1124/jpet.113.205419. Epub 2013 Jun 21.</citation>
    <PMID>23792410</PMID>
  </results_reference>
  <results_reference>
    <citation>de Haan J, Verheecke M, Van Calsteren K, Van Calster B, Shmakov RG, Mhallem Gziri M, Halaska MJ, Fruscio R, Lok CAR, Boere IA, Zola P, Ottevanger PB, de Groot CJM, Peccatori FA, Dahl Steffensen K, Cardonick EH, Polushkina E, Rob L, Ceppi L, Sukhikh GT, Han SN, Amant F; International Network on Cancer and Infertility Pregnancy (INCIP). Oncological management and obstetric and neonatal outcomes for women diagnosed with cancer during pregnancy: a 20-year international cohort study of 1170 patients. Lancet Oncol. 2018 Mar;19(3):337-346. doi: 10.1016/S1470-2045(18)30059-7. Epub 2018 Jan 26.</citation>
    <PMID>29395867</PMID>
  </results_reference>
  <results_reference>
    <citation>de Haan J, van Thienen JV, Casaer M, Hannivoort RA, Van Calsteren K, van Tuyl M, van Gerwen MM, Debeer A, Amant F, Painter RC. Severe Adverse Reaction to Vemurafenib in a Pregnant Woman with Metastatic Melanoma. Case Rep Oncol. 2018 Feb 15;11(1):119-124. doi: 10.1159/000487128. eCollection 2018 Jan-Apr.</citation>
    <PMID>29606950</PMID>
  </results_reference>
  <results_reference>
    <citation>Boucek J, de Haan J, Halaska MJ, Plzak J, Van Calsteren K, de Groot CJM, Dahl Steffensen K, Fruscio R, Massolt ET, Klaritsch P, Zola P, Amant F; International Network on Cancer, Infertility, and Pregnancy. Maternal and obstetrical outcome in 35 cases of well-differentiated thyroid carcinoma during pregnancy. Laryngoscope. 2017 Oct 8. doi: 10.1002/lary.26936. [Epub ahead of print]</citation>
    <PMID>28988434</PMID>
  </results_reference>
  <results_reference>
    <citation>de Haan J, Lok CA, de Groot CJ, Crijns MB, Van Calsteren K, Dahl Steffensen K, Halaska MJ, Altintas S, Boere IA, Fruscio R, Kolawa W, Witteveen PO, Amant F; International Network on Cancer, Infertility and Pregnancy (INCIP). Melanoma during pregnancy: a report of 60 pregnancies complicated by melanoma. Melanoma Res. 2017 Jun;27(3):218-223. doi: 10.1097/CMR.0000000000000327.</citation>
    <PMID>28099365</PMID>
  </results_reference>
  <results_reference>
    <citation>Verheecke M, Cortès Calabuig A, Finalet Ferreiro J, Brys V, Van Bree R, Verbist G, Everaert T, Leemans L, Gziri MM, Boere I, Halaska MJ, Vanhoudt J, Amant F, Van Calsteren K. Genetic and microscopic assessment of the human chemotherapy-exposed placenta reveals possible pathways contributive to fetal growth restriction. Placenta. 2018 Apr;64:61-70. doi: 10.1016/j.placenta.2018.03.002. Epub 2018 Mar 9.</citation>
    <PMID>29626982</PMID>
  </results_reference>
  <results_reference>
    <citation>Vandenbroucke, T., Verheecke, M., Fumagalli, M., Lok, C., &amp; Amant, F. (2017) Effects of cancer treatment during pregnancy on fetal and child development. The Lancet Child and Adolescent Health 2017, 1, 302-310. DOI:10.1016/S2352-4642(17)30091-3</citation>
  </results_reference>
  <results_reference>
    <citation>Gziri MM, Brunée L, Cayphas C, Prigogine T, Van Raemdonck D, Amant F, Hubinont C. Low-grade bronchial mucoepidermoid carcinoma during pregnancy successfully treated by lobectomy. J Obstet Gynaecol. 2017 Nov;37(8):1082-1084. doi: 10.1080/01443615.2017.1308325. Epub 2017 Jun 1.</citation>
    <PMID>28569562</PMID>
  </results_reference>
  <results_reference>
    <citation>de Haan J, Van Calsteren K, Lok CAR, de Groot CJM, Amant F. Comment on &quot;Maternal and perinatal outcomes in pregnancy-associated melanoma. Report of two cases and a systematic literature review&quot;. Eur J Obstet Gynecol Reprod Biol. 2017 Sep;216:261-262. doi: 10.1016/j.ejogrb.2017.07.025. Epub 2017 Jul 23.</citation>
    <PMID>28768572</PMID>
  </results_reference>
  <results_reference>
    <citation>Vandenbroucke T, Han SN, Van Calsteren K, Wilderjans TF, Van den Bergh BRH, Claes L, Amant F. Psychological distress and cognitive coping in pregnant women diagnosed with cancer and their partners. Psychooncology. 2017 Aug;26(8):1215-1221. doi: 10.1002/pon.4301. Epub 2016 Nov 21.</citation>
    <PMID>27859911</PMID>
  </results_reference>
  <results_reference>
    <citation>Gziri MM, Han SN, Amant F. Use of general anesthesia and sentinel node procedure during pregnancy. J Surg Oncol. 2012 Dec;106(8):1008. doi: 10.1002/jso.23164. Epub 2012 Jun 4.</citation>
    <PMID>22674350</PMID>
  </results_reference>
  <results_reference>
    <citation>Lambrechts S, Van Calsteren K, Capoen A, Op De Beeck K, Joniau S, Timmerman D, Amant F. Polypoid endometriosis of the bladder during pregnancy mimicking urachal carcinoma. Ultrasound Obstet Gynecol. 2011 Oct;38(4):475-8. doi: 10.1002/uog.8985. Epub 2011 Sep 6.</citation>
    <PMID>21374752</PMID>
  </results_reference>
  <results_reference>
    <citation>Van Calsteren K, Verbesselt R, Van Bree R, Heyns L, de Bruijn E, de Hoon J, Amant F. Substantial variation in transplacental transfer of chemotherapeutic agents in a mouse model. Reprod Sci. 2011 Jan;18(1):57-63. doi: 10.1177/1933719110379650. Epub 2010 Sep 8.</citation>
    <PMID>20826505</PMID>
  </results_reference>
  <results_reference>
    <citation>Van Calsteren K, Verbesselt R, Beijnen J, Devlieger R, De Catte L, Chai DC, Van Bree R, Heyns L, de Hoon J, Amant F. Transplacental transfer of anthracyclines, vinblastine, and 4-hydroxy-cyclophosphamide in a baboon model. Gynecol Oncol. 2010 Dec;119(3):594-600. doi: 10.1016/j.ygyno.2010.08.019. Epub 2010 Sep 17.</citation>
    <PMID>20846713</PMID>
  </results_reference>
  <results_reference>
    <citation>Calsteren KV, Verbesselt R, Devlieger R, De Catte L, Chai DC, Van Bree R, Heyns L, Beijnen J, Demarsin S, de Bruijn E, de Hoon J, Amant F. Transplacental transfer of paclitaxel, docetaxel, carboplatin, and trastuzumab in a baboon model. Int J Gynecol Cancer. 2010 Dec;20(9):1456-64. doi: 10.1111/IGC.0b013e3181fb18c8.</citation>
    <PMID>21307819</PMID>
  </results_reference>
  <results_reference>
    <citation>Van Calsteren K, Verbesselt R, Ottevanger N, Halaska M, Heyns L, Van Bree R, de Bruijn E, Chai D, Delforge M, Noens L, Renard V, Witteveen E, Rob L, de Hoon J, Amant F. Pharmacokinetics of chemotherapeutic agents in pregnancy: a preclinical and clinical study. Acta Obstet Gynecol Scand. 2010 Oct;89(10):1338-45. doi: 10.3109/00016349.2010.512070.</citation>
    <PMID>20846067</PMID>
  </results_reference>
  <results_reference>
    <citation>Van Calsteren K, Hanssens M, Moerman P, Orye G, Bielen D, Vergote I, Amant F. Successful conservative treatment of endocervical adenocarcinoma stage Ib1 diagnosed early in pregnancy. Acta Obstet Gynecol Scand. 2008;87(2):250-3. doi: 10.1080/00016340701870794.</citation>
    <PMID>18231896</PMID>
  </results_reference>
  <results_reference>
    <citation>Van Calsteren K, Van Mensel K, Joniau S, Oyen R, Hanssens M, Amant F, Van Poppel H. Urachal carcinoma during pregnancy. Urology. 2006 Jun;67(6):1290.e19-21.</citation>
    <PMID>16750250</PMID>
  </results_reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 25, 2006</study_first_submitted>
  <study_first_submitted_qc>May 25, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2006</study_first_posted>
  <last_update_submitted>May 18, 2018</last_update_submitted>
  <last_update_submitted_qc>May 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Gasthuisberg</investigator_affiliation>
    <investigator_full_name>Frederic Amant</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <keyword>pregnancy</keyword>
  <keyword>in utero</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>radiotherapy</keyword>
  <keyword>cancer</keyword>
  <keyword>offspring</keyword>
  <keyword>neonatal</keyword>
  <keyword>long term</keyword>
  <keyword>follow up</keyword>
  <keyword>cancer during pregnancy</keyword>
  <keyword>chemotherapy and radiotherapy during pregnancy</keyword>
  <keyword>long term follow up of children</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

